Results 41 to 50 of about 280,456 (250)

New approaches in detection and treatment of familial hypercholesterolemia [PDF]

, 2015
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that clinically leads to increased low density lipoprotein-cholesterol (LDL-C) levels. As a consequence, FH patients are at high risk for cardiovascular disease (CVD). Mutations
Hartgers, ML, Hovingh, GK, Ray, KK
core   +12 more sources

Role of lipoprotein apheresis in the management of familial hypercholesterolemia

Global Journal of Transfusion Medicine, 2021
Familial Hypercholesterolemia (FH) is an autosomal dominant disorder due to a congenital absence of low-density lipoprotein receptor (LDL-R) that transports cholesterol-carrying lipoprotein particles into cells.
Shamanna Seshadri Iyengar, Ambuja Kantharaj, Chandrashekar Shivaram, D S Hemantha Kumara, Roopa Murgod, G Shreedhara   +5 more
doaj   +1 more source

Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. [PDF]

Lancet Child Adolesc Health
Reijman MD, Tromp TR, Hutten BA, Hovingh GK, Blom DJ, Catapano AL, Cuchel M, Dann EJ, Gallo A, Hudgins LC, Raal FJ, Ray KK, Sadiq F, Soran H, Groothoff JW, Wiegman A, Kusters DM, Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (HICC), Children with Homozygous Hypercholesterolemia on Lipoprotein Apheresis: an International Registry (CHAIN) consortia.   +18 more
europepmc   +2 more sources

Membranous nephropathy complicated by immune thrombocytopenia treated with low-density lipoprotein apheresis: a case report and literature review. [PDF]

CEN Case Rep, 2022
Nishizawa K, Yamashita T, Ogawa Y, Kobayashi H.   +3 more
europepmc   +2 more sources

Beyond lipids: Systemic effects of lipoprotein apheresis [PDF]

Transfusion, EarlyView.
Menatalla K. Nadim, Yamac Akgun
openalex   +2 more sources

Clinical impact of a novel lipoprotein apheresis treatment on no‐option chronic limb‐threatening ischemia: Result from the REDUCTION VISCOSITY study

Therapeutic apheresis and dialysis, 2023
Lipoprotein apheresis (LA) is a possible adjunct treatment for no‐option chronic limb‐threatening ischemia (CLTI). This study aimed to assess the impact of a novel LA for no‐option CLTI.
Shunsuke Kojima, T. Nakama, Toshihiko Suzuki, K. Obunai, Hiroyuki Watanabe   +4 more
semanticscholar   +1 more source

Therapeutic apheresis in kidney diseases: an updated review

Renal Failure, 2022
Besides conventional medical therapies, therapeutic apheresis has become an important adjunctive or alternative therapeutic option to immunosuppressive agents for primary or secondary kidney diseases and kidney transplantation.
Yi-Yuan Chen, Xin Sun, Wei Huang, Fang-Fang He, Chun Zhang   +4 more
doaj   +1 more source

Comorbidity in lipoprotein apheresis: Their role in the era of new lipid‐lowering therapies

Journal of clinical apheresis, 2023
Despite advance in pharmacotherapy of lipid disorders, lipoprotein apheresis (LA) plays a leading role in the management of severe hypercholesterolemia and in atherosclerosis prevention.
F. Sbrana, M. Pianelli, R. Luciani, F. Bigazzi, Carmen Corciulo, A. Ripoli, T. Sampietro, B. Dal Pino   +7 more
semanticscholar   +1 more source

Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis. [PDF]

Nutrients, 2019
Weylandt KH, Schmöcker C, Ostermann AI, Kutzner L, Willenberg I, Kiesler S, Steinhagen-Thiessen E, Schebb NH, Kassner U.   +8 more
europepmc   +3 more sources

The scientific basis and future of lipoprotein apheresis

Therapeutic apheresis and dialysis, 2021
Lipoprotein apheresis plays a vital role in the management of the severe hyperlipidemias that predispose to atherosclerosis. Determinants of efficacy are the acute reduction in lipoproteins achieved by each apheresis procedure, their frequency, and the ...
G. Thompson
semanticscholar   +1 more source